Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it enclosed a Press Release as regards launch of a novel fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients under the brand name DIFIZMA® in India.
The above information is a part of company’s filings submitted to BSE.